CONQUEST is a platform clinical trial designed by the SRF to accelerate the development of potential new treatments for scleroderma. With 142 sites across 24 countries, CONQUEST is bringing together scleroderma treatment centers worldwide to advance collaborative research, with the first iteration of the trial focused on systemic sclerosis–associated interstitial lung disease (SSc-ILD).
On our website, you can use our interactive global map to explore all CONQUEST locations and see where the trial is currently enrolling. From there, you can connect directly with sites to learn more about eligibility and next steps.
